These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37451430)

  • 1. Country of birth is associated with discrepancies in the prescription of two-drug regimens in successfully treated people with HIV in France.
    Palich R; Hentzien M; Hocqueloux L; Duvivier C; Allavena C; Huleux T; Makinson A; Rey D; Delobel P; Cuzin L;
    AIDS; 2023 Oct; 37(12):1891-1896. PubMed ID: 37451430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Country of birth is associated with antiretroviral therapy choice in treatment-naive persons with HIV in France.
    Palich R; Hentzien M; Hocqueloux L; Duvivier C; Allavena C; Huleux T; Delobel P; Makinson A; Rey D; Cuzin L;
    AIDS; 2023 Jul; 37(9):1459-1466. PubMed ID: 37115905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
    Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
    HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
    Deschanvres C; Reynes J; Lamaury I; Rey D; Palich R; Bani-Sadr F; Robineau O; Duvivier C; Hocqueloux L; Cuzin L; Joly V; Raffi F; Cabie A; Allavena C;
    J Antimicrob Chemother; 2021 Dec; 77(1):196-204. PubMed ID: 34651192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients Beyond the Indication of Clinical Trials: 48 Weeks' Results.
    Arancón Pardo A; Moreno Palomino M; Jiménez-Nácher I; Moreno F; González Fernández MÁ; González-García J; Herrero Ambrosio A
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):761-767. PubMed ID: 34465135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
    Hui X; Gan X; Li Q; Sun W
    Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
    Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
    Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
    Hidalgo-Tenorio C; Vinuesa D; García-Vallecillos C; Muñoz-Medina L; Sequera S; Javier R; López-Ruz MÁ; Sadyrbaeva-Dolgova S; Pasquau J
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real world use of dolutegravir two drug regimens.
    Bowman C; Ambrose A; Kanitkar T; Flores K; Simoes P; Hart J; Hunter A; Akodu J; Barber TJ
    AIDS; 2023 Apr; 37(5):785-788. PubMed ID: 36728219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
    Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
    Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Cervo A; Valenti D; Callegaro A; Mussini C
    BMC Infect Dis; 2022 Oct; 22(1):782. PubMed ID: 36224538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
    Cento V; Perno CF
    J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
    Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
    Gagliardini R; Baccini M; Modica S; Montagnani F; Zanelli G; Borghetti A; Dreassi E; Lombardi F; Pecorari M; Borghi V; Callegaro A; Micheli V; Lodi MA; Rossetti B; Zazzi M;
    J Glob Antimicrob Resist; 2022 Mar; 28():274-281. PubMed ID: 35092828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
    Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
    Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC
    Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
    Fabbiani M; Rossetti B; Ciccullo A; Oreni L; Lagi F; Celani L; Colafigli M; De Vito A; Mazzitelli M; Dusina A; Durante M; Montagnani F; Rusconi S; Capetti A; Sterrantino G; D'Ettorre G; Di Giambenedetto S;
    HIV Med; 2021 Oct; 22(9):843-853. PubMed ID: 34318591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
    N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.